APA (7th ed.) Citation

Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., . . . Delaporte, E. (2017). First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial. Lancet, 389(10083), 2031. https://doi.org/10.1016/S0140-6736(17)30070-3

Chicago Style (17th ed.) Citation

Joly, Pascal, et al. "First-line Rituximab Combined with Short-term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-group, Open-label Randomised Trial." Lancet 389, no. 10083 (2017): 2031. https://doi.org/10.1016/S0140-6736(17)30070-3.

MLA (9th ed.) Citation

Joly, Pascal, et al. "First-line Rituximab Combined with Short-term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-group, Open-label Randomised Trial." Lancet, vol. 389, no. 10083, 2017, p. 2031, https://doi.org/10.1016/S0140-6736(17)30070-3.